Th2 inflammation plays a central role

EoE is now considered a type 2-mediated immune disease that is often associated with atopic diseases such as atopic dermatitis, asthma and food allergies. In addition to acid blockers (PPI) and steroids, a biologic, dupilumab, is now also available for treatment. Dupilumab specifically targets key cytokines of type 2 inflammation. Dietary measures are still recommended. And if strictures have already formed, dilatation should be considered if necessary.